|
|
||||||||
B
Intercollege Physiology Program, Noll Physiological Research Center, Pennsylvania State University, University Park, Pennsylvania 16802
| |
ABSTRACT |
|---|
|
|
|---|
Macrophage migration inhibitory factor (MIF) is an inflammatory
cytokine secreted by several cell types, including mononuclear and
pituitary cells. It has also been shown to counteract cortisol-induced inhibition of inflammatory cytokine secretion. The purpose of this
study was to determine whether MIF antagonized the effect of
hydrocortisone on the NF-
B/I
B signal transduction pathway in
lipopolysaccharide (LPS)-stimulated human peripheral blood mononuclear
cells. Physiological doses of hydrocortisone (50-200 ng/ml)
diminished both the LPS-stimulated decrease in cytosolic I
B
levels and the subsequent increase in nuclear NF-
B DNA binding. In
the presence of both LPS and hydrocortisone, 1 ng/ml of MIF antagonized
the effects of hydrocortisone, resulting in decreased cytosolic
I
B
levels (P < 0.05) and increased nuclear
NF-
B DNA binding (P < 0.05). In the absence of
hydrocortisone, MIF had no effect on LPS-induced decreases in I
B
.
In the absence of LPS, MIF inhibited hydrocortisone-induced increases
in I
B
(P = 0.03). Thus the mechanism by which MIF
antagonizes the effect of hydrocortisone on the NF-kB/I
B signal
transduction pathway is through inhibiting the ability of
hydrocortisone to increase cytosolic I
B
.
monocytes; glucocorticoids; NF-
B
| |
INTRODUCTION |
|---|
|
|
|---|
MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) was originally described as a T cell-derived lymphokine that prevented the random migration of macrophages (7). More recent data indicate that MIF has a much broader role within the immune response. For example, MIF increased inducible nitric oxide synthase expression and decreased footpad lesions after Leishmania major challenge in mice (19). Furthermore, administration of anti-MIF antibodies to mice attenuated the frequency of rheumatoid arthritis development in mice and decreased the secretion of collagen II antibodies (12). MIF is secreted by cells other than T lymphocytes, further supporting its broader role in the inflammatory response. Constitutive expression of MIF has been detected in many tissues, including eye (18), kidney (11), skin (15), and gonads (17).
MIF also appears to be a neuroendocrine modulator of systemic
inflammation. Administration of recombinant MIF to mice potentiated endotoxemia, whereas anti-MIF antibodies prevented the development of
endotoxic shock (4). Furthermore, mice lacking the MIF
gene were resistant to the lethal effects of high doses of
lipopolysaccharide (LPS) and had lower plasma tumor necrosis
factor-
(TNF-
) levels than wild-type mice (5).
A feedback mechanism exists between the hypothalamic-pituitary-adrenal
(HPA) axis and mononuclear cells, such that glucocorticoids (cortisol)
inhibit inflammatory cytokine secretion during inflammation, thereby limiting the inflammatory response. Constitutive preformed MIF
is stored by corticotropic cells of the anterior pituitary and is
released during stress (6) or in response to LPS
stimulation (4). Thus MIF may also be involved in the
regulation of the inflammatory response by the HPA axis. Interestingly,
Calandra et al. (6) demonstrated that MIF could counteract
glucocorticoid-induced inhibition of inflammatory cytokine secretion
[interleukin (IL)-1
, IL-6, IL-8, and TNF-
].
The mechanism by which MIF counteracts glucocorticoid-induced
inhibition of inflammation has not been fully elucidated. However, there are several possible pathways where MIF and glucocorticoids may
interact. One such pathway involves the activation of the transcriptional factor, NF-
B. Many inflammatory mediators are regulated by NF-
B, including inflammatory cytokines (IL-1
and TNF-
), adhesion molecules, immunoreceptors, and acute-phase proteins (3). NF-
B is a ubiquitous transcriptional factor in
immune cells and is activated by inflammatory stimuli (cytokines, LPS, and viruses). The classical NF-
B is a heterodimeric protein that consists of p50 and p65 subunits, which reside in the cytosol. Upon
activation, NF-
B is released from an inhibitory protein (I
B
),
translocates to the nucleus, and activates transcription (2,
16). Glucocorticoids prevent NF-
B activation in part by
increasing the expression of I
B
(1, 13), which keeps NF-
B bound in the cytosol and thus prevents gene expression of inflammatory mediators (Fig. 1).
|
The purpose of this study was to examine the antagonism between
glucocorticoids and MIF at the intracellular level in human mononuclear
cells. Specifically, the hypothesis that MIF counteracts the influence
of hydrocortisone on cytosolic I
B
concentrations and NF-
B
activation was tested. In addition, experiments were performed to
determine whether MIF enhanced LPS-induced breakdown of IkB
[experiment 2 (Exp-2) in Fig. 1], inhibited
hydrocortisone-induced synthesis of IkB [experiment 3 (Exp-3)], or bound directly to hydrocortisone, interfering with
cellular binding [experiment 4 (Exp-4)].
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Subjects. All subjects were healthy, were not taking any medication, and gave informed consent to participate in this study. The first series of experiments, examining MIF and hydrocortisone interactions in LPS-stimulated mononuclear cells, included seven subjects (27.6 ± 3.4 yr of age). Later studies examining pairwise combinations of LPS, MIF, and hydrocortisone involved mononuclear cells from six subjects (33 ± 10.3 yr of age). All procedures were approved by the Pennsylvania State University Human Investigation Review Committee.
Blood samples, cell isolation, and culture.
A venous blood sample was drawn from each subject between 8:00 and 9:00
AM via antecubital vein into a heparinzed syringe. All subjects had
fasted for ~12 h before having their blood drawn. Peripheral blood
mononuclear cells (PBMC) were isolated by density centrifugation with
Ficoll-Hypaque (Histopaque; Sigma, St. Louis, MO). The mononuclear cell
layer was aspirated and washed three times with nonpyrogenic 0.9%
NaCl. The cells were resuspended in phenol red-free RPMI supplemented
with 100 U/ml penicillin, 100 µg/ml streptomycin, 100 mM Hepes, 0.2 mM L-glutamine (all from Sigma), and 2% TCH serum
replacement (ICN Pharmaceuticals, Costa Mesa, CA). The cells were
cultured at a density of 5 × 106 cells/ml and were
preincubated with sodium hydrocortisone (Solu-Cortex, Upjohn,
Kalamazoo, MI) in concentrations of 0, 50, 100, and 200 ng/ml with 0, 0.1, or 1 ng/ml of recombinant human MIF (R & D Systems, Minneapolis,
MN) for 1 h. The cells were then stimulated with 1 µg/ml LPS
(Escherichia coli 055:B5, Sigma) or remained unstimulated.
For analysis of the NF-
B/I
B signal transduction process, cell
cultures were incubated for 30 min at 37°C in a humidified 5%
CO2 chamber, followed by extraction of the nuclear and
cytoplasmic fractions as described in the next section. All containers
used for cell culture were disposable and endotoxin-free: all solutions
were injectable grade or endotoxin tested.
Cytoplasmic and nuclear cell extraction.
Cytoplasmic and nuclear extracts were prepared using a modified method
by Dignam et al. (9). After incubation with LPS, the cells
were transferred to sterile 1.5-ml microcentrifuge tubes and placed on
ice. Cells were centrifuged for 8 min at 750 g and washed
with 1 ml of sterile ice-cold PBS. The packed cell pellet was
resuspended in 100 µl of solution A [10 mM HEPES, 1.5 mM
MgCl2, 10 mM KCl, and 0.5 mM dithiothreitol (DTT)] and a
protease inhibitor cocktail [100 mM 4-(2-aminoethyl)benzenesulfonyl
fluoride, 1 µg/ml pepstatin A, 3 µg/ml
trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane, 4 µg/ml bestatin, 10 µg/ml leupeptin, and 3 µg/ml aprotinin, all from Sigma] and was placed on ice for 10 min to allow the cells to
swell. Nonidet-40 (Boehringer Mannheim, Indianapolis, IN) was added to
all cells at a final concentration of 0.6%, and the cells were gently
agitated to disrupt the cell membrane. The nuclei were pelleted by
centrifugation for 3 min at 500 g. The supernatant containing the cytosolic extract was transferred to a new
microcentrifuge tube and centrifuged for 10 min at 18,000 g.
The supernatant was collected, assayed for total protein content by the
Bio-Rad Dc protein assay (Bio-Rad, Hercules, CA),
immediately frozen in liquid nitrogen, and stored at
70°C. The
nuclear pellet was washed with 500 µl of solution A and
transferred to a 0.5-ml microcentrifuge tube and centrifuged; packed
nuclei were resuspended in 20 µl of solution B (20 mM
HEPES, 20% glycerol, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT, and protease inhibitor cocktail) and placed on a rocker at
4°C for 1 h to extract the nuclear proteins. The samples were
centrifuged for 10 min at 18,000 g, and the supernatant was
collected and assayed for total protein content by the Bio-Rad protein
assay, immediately frozen in liquid nitrogen, and stored at
70°C.
Electrophoresis and immunoblot.
For electrophoresis, 10 µg of total protein from individual
samples were loaded into the lanes of a 10% SDS denaturing
polyacrylamide gel and elecrophoretically separated. Proteins were then
electrophoretically transferred onto Immobilin-P membranes (Millipore).
The membranes were blocked with Tris-buffered saline (TBS), pH 6.7, containing 0.5% Tween 20 and 5% nonfat dry milk (BLOTTO) for a
minimum of 2 h. For I
B
detection, the membranes were
incubated overnight at 4°C with rabbit polyclonal anti-human I
B
(epitope corresponding to the amino-terminal domain of I
B
; Santa
Cruz Biotechnology, Santa Cruz, CA) diluted 1:800 in BLOTTO. After the
membranes were washed twice for 7 min each in TBS containing 0.5%
Tween 20 (TBST), they were incubated for 30 min in secondary
horseradish peroxidase-labeled anti-rabbit IgG (Santa Cruz
Biotechnology) diluted 1:7,500 in BLOTTO, and then washed three times
for 5 min in TBST followed by one wash in TBS. The proteins were
detected by treating the membranes with enhanced chemiluminescence
assay reagents (Amersham Life Science, Arlington Heights, IL) and
exposing them to film for 90 s. I
B
levels were determined by
densitometry using the ImageQuant analysis program (Molecular Dynamics,
Sunnyvale, CA).
Electrophorectic mobility shift assay.
To determine DNA-protein interactions, 2 µg of each nuclear extract
were added to reaction buffer (25 mM HEPES, pH 7.6, 100 mM KCl,
0.1 mM EDTA, and 10% glycerol) containing 0.5 mg poly (dI-dC),
and 1 mM DTT, and randomly primed 32P-labeled NF-
B
oligonucleotide probe (AAAGAAATTCCAAAGAGT) containing ~2 × 105 counts/min (cpm). The NF-
B probe was a generous gift
from Dr. Shao-Cong Sun, Department of Microbiology and Immunology,
Pennsylvania State University, Hershey Medical Center. After incubation
for 10 min at room temperature, 1.5 µl of loading buffer (0.25%
bromophenol blue in 10 mM Tris-1 mM EDTA buffer, pH 8.0) were added to
all samples to stop the reaction. Samples were loaded onto a 5% native acrylamide gel and prerun for 1 h. The samples were
electrophoresed for 3 h, and the gel was dried for 1 h at
80°C, followed by exposure to X-ray film for periods ranging from
4 h to overnight. NF-
B levels were determined by densitometry
by use of the ImageQuant analysis program (Molecular Dynamics). For
supershifting assays, 1 µl of anti-p50 or anti-p65 antibodies (Santa
Cruz Biotechnology) was added before addition of loading buffer, and
the mixture was incubated for 30 min followed by addition of 1.5 ml of
loading buffer and electrophoresis, as described above. Additionally, for competition assays, a 200 molar excess of unlabeled probe was added
to the reaction mixture.
[3H]hydrocortisone binding. MIF (100 ng/ml) was incubated with 4.5 ng/ml [3H]hydrocortisone (1 µCi) in PBS for 2 h at room temperature. After incubation, 20 µl of the mixture were applied to a PD-10 column (Pharmacia, Piscataway, NJ), and 0.5-ml fractions were collected. The fractions were analyzed by liquid scintillation on a Beckman LS6500 counter (Fullerton, CA). In a second run, a cytochrome c standard (mol wt 12,400) was applied to the column, and its elution volume was determined spectrophotometrically at A280. The molecular mass of MIF is 12,000 Da, and that of [3H]hydrocortisone is 375 Da.
PBMC (4 × 106 cells/ml) were incubated with MIF (0, 1, 10, and 100 ng/ml) and [3H]hydrocortisone (11 ng/ml, 20 µCi) for 2 h at room temperature. Additional cells were incubated with [3H]hydrocortisone alone (total binding) or [3H]hydrocortisone and 2 µg/ml unlabeled hydrocortisone (180-fold excess, nonspecific binding). After 2 h, the cell suspensions were centrifuged through an oil mixture [1 part dimethyl silicon (Thomas Scientific, Swedesboro, NJ) and 2 parts silicone AR200 (Gallard-Schlesinger, Carle Place, NY)] to separate the cells from the supernatant. The pellet was collected, and incorporation of radioactivity was determined by liquid scintillation as described for the fractions. Specific binding was calculated by subtracting the nonspecific binding from the binding in the other conditions.Statistical analysis.
Densitometric values for NF-
B activation from the electrophorectic
mobility shift assay (EMSA) and I
B
levels from the Western immunoblot were determined for all subjects and normalized to the
appropriate control condition for each experiment. Means were calculated for the normalized values, and the data are expressed as
means ± SE. The data examining the interaction of hydrocortisone and MIF in LPS-stimulated cells were analyzed by a two-factor ANOVA,
with Dunnett's post hoc analysis to determine significant differences
from control. All other data were analyzed by a one-way ANOVA, using
linear contrasts to determine significant differences between the
groups. Significance was accepted at P < 0.05 for all
data. Data were analyzed using SuperAnova v1.11 software (Abacus Concepts, Berkeley, CA).
| |
RESULTS |
|---|
|
|
|---|
Influence of hydrocortisone on NF-
B.
Incubation of mononuclear cells with 1 µg/ml of LPS for 30 min
resulted in activation of NF-
B as demonstrated by an increased mobility shift of the NF-
B oligo probe above the control
(unstimulated) condition in the nuclear fractions of mononuclear cells
(lanes 1 and 2, Fig.
2A). Preincubation of the
cells with physiological concentrations of hydrocortisone attenuated
the LPS-stimulated activation of NF-
B (lanes 3-5).
Densitometric analysis indicated that LPS caused a 120% increase in
NF-
B activation in the nuclear fraction above resting, unstimulated
conditions (Fig. 2B). Additionally, preincubation of the
cells with hydrocortisone at concentrations similar to normal
circulating plasma levels (50-250 ng/ml) decreased LPS-stimulated
activation of NF-
B. However, these concentrations of hydrocortisone
did not completely prevent NF-
B activation (i.e., return to the
control condition). Probe specificity was verified by competition and
supershift experiments, as shown in Fig.
3.
|
|
Influence of hydrocortisone on I
B
.
Incubation of mononuclear cells with LPS resulted in reduced cytosolic
I
B
concentrations compared with the unstimulated control
(lanes 1 and 2, Fig. 2C).
Preincubation of the cells with hydrocortisone attenuated the
LPS-stimulated decreases in cytosolic I
B
(lanes
3-5). Densitometric analysis revealed that LPS decreased cytosolic I
B
by 25% compared with the unstimulated control, whereas preincubation with hydrocortisone diminished this response (Fig. 2D). There was a reciprocal correspondence between the
amount of NF-
B in the nucleus and the amount of I
B
detected in
the cytosol (Fig. 2, B and D); however, there was
a large degree of variation in the influence of hydrocortisone on
I
B
. Therefore, subsequent analyses of the data examining the
antagonism between MIF and hydrocortisone were normalized to each dose
of hydrocortisone.
Interaction of MIF and hydrocortisone on NF-
B.
To test the hypothesis that MIF counteracts hydrocortisone activity,
PBMC were preincubated with MIF (0, 0.1, 1 ng/ml) along with
hydrocortisone before LPS stimulation. As shown in Fig.
4A, MIF partially reversed the
hydrocortisone-mediated inhibition of NF-
B. To quantify the
antagonism of MIF on hydrocortisone activity, densitometric analyses
were normalized to the hydrocortisone response without MIF for each
dose of hydrocortisone. As shown in Fig. 4B, both doses of
MIF increased NF-
B activation above that observed with
hydrocortisone and LPS (P < 0.05, across all doses of
hydrocortisone); however, neither dose of MIF returned NF-
B to the
levels observed with LPS alone. MIF alone (without LPS) did not change
NF-
B from the unstimulated control level: densitometric analysis of
the NF-
B activation from such cultures incubated with 1 ng/ml was
117 ± 17% of the control condition (n = 6, data
not shown).
|
Interaction of MIF and hydrocortisone on I
B
.
Hydrocortisone is reported to inhibit NF-
B activation by increasing
cytosolic I
B
, thereby preventing NF-
B translocation to the
nucleus. Therefore, we sought to determine whether MIF prevented
hydrocortisone-induced increases in cytosolic I
B
. Preincubation
of cells with hydrocortisone and MIF before LPS stimulation resulted in
levels of I
B
that were lower than those observed with
preincubation of hydrocortisone (Fig.
5A). To quantify the
antagonism of MIF on hydrocortisone activity, densitometric analyses
were normalized to the hydrocortisone response without MIF for each
dose of hydrocortisone. As shown in Fig. 5B, MIF attenuated
the hydrocortisone-mediated preservation of cytosolic I
B
. The
higher dose of MIF (1 ng/ml) significantly decreased cytosolic I
B
across the doses of hydrocortisone (P < 0.05), whereas
0.1 ng/ml had no statistically significant effect.
|
B
or by preventing the
hydrocortisone-induced increase in I
B
synthesis. As shown in Fig.
6, MIF did not enhance the
LPS-stimulated degradation of I
B
. LPS alone resulted in a 28%
decrease in cytosolic I
B
compared with controls, whereas LPS plus
MIF resulted in a 13% decrease. The influence of MIF alone (without
LPS) was examined in a separate experiment, and no effect on I
B
degradation was observed (98 ± 20.3% of control, data not
shown).
|
B
, the
ability of MIF to prevent the hydrocortisone-induced increase in
cytosolic I
B
was examined. In the absence of LPS, MIF prevented the direct increase in cytosolic I
B
by hydrocortisone. As shown in Fig. 7, preincubation of mononuclear
cells with 200 ng/ml of hydrocortisone alone increased cytosolic
I
B
levels 43% above the control condition (no hydrocortisone),
and 1 ng/ml of MIF completely reversed the hydrocortisone-induced
increase in I
B
(P = 0.03). Incubation of the
cells with 100 ng/ml of hydrocortisone resulted in a modest increase in
I
B
(20% above the control), whereas 1 ng/ml of MIF did not
result in any detectable changes in I
B
because of the small
hydrocortisone-induced increases in I
B
.
|
Binding interactions between MIF and hydrocortisone. The possibility that MIF modulated hydrocortisone by acting as a binding protein that prevented hydrocortisone association with target cells was tested in two ways: first, by determining whether MIF directly bound [3H]hydrocortisone in solution, and second, by determining whether MIF interfered with specific binding of [3H]hydrocortisone in PBMC.
After incubation of MIF with [3H]hydrocortisone and passage of this mixture through a gel filtration column, radioactivity eluted in essentially a single peak at an elution volume indicating a molecular size of <1,000 Da (Fig. 8A). Less than 4% of the radioactivity eluted at the same volume as cytochrome c (which could represent [3H]hydrocortisone bound to MIF).
|
B experiments) was a small (14%) reduction in specific binding observed (Fig.
8B).
| |
DISCUSSION |
|---|
|
|
|---|
The major finding of this study is that MIF counteracts the
hydrocortisone-mediated inhibition of NF-
B. The mechanism for the
counterregulatory action of MIF involves prevention of
hydrocortisone-induced increases in cytosolic I
B
. As a result,
NF-
B can translocate to the nucleus and activate transcription, even
in the presence of normal physiological concentrations of
hydrocortisone. Additionally, hydrocortisone, in concentrations
normally found in the plasma, inhibits NF-
B activation in
LPS-stimulated PBMC. This extends previous findings based on
pharmacological concentrations of glucocorticoids (13).
The present study tested several cellular pathways that could account
for the counterregulatory effect of MIF on hydrocortisone activity. MIF
could activate an intracellular pathway similar to LPS, leading to
I
B
kinase (IKK) activation and ultimate I
B
degradation,
thus overriding the hydrocortisone induced-inhibition of NF-
B
activation. If this were the case, then MIF should have enhanced
I
B
degradation in LPS-stimulated cells. However, this study
demonstrated that LPS stimulation resulted in a 28% decrease in
cytosolic I
B
, and preincubation with MIF did not significantly change the I
B
levels compared with LPS alone (see Fig. 6). Thus, it is unlikely that MIF is functioning through an intracellular pathway, similar to LPS, that leads to I
B
degradation.
Furthermore, MIF alone did not alter cytosolic I
B
levels.
Alternatively, MIF may interfere with hydrocortisone-induced I
B
synthesis. Hydrocortisone increases I
B
expression, thus preventing NF-
B translocation to the nucleus and activation of transcription (1, 13). In the present study, incubation of unstimulated mononuclear cells with 200 ng/ml of hydrocortisone significantly increased cytosolic I
B
. The addition of MIF was able to prevent this hydrocortisone-induced increase in I
B
. Thus
one counterregulatory effect of MIF is the prevention of hydrocortisone-induced I
B
synthesis.
Hydrocortisone also prevents NF-
B from binding to DNA in the
nucleus. Hydrocortisone bound to the glucocorticoid receptor migrates
to the nucleus, where it competes for DNA binding sites with NF-
B,
thereby preventing NF-
B-dependent transcription (14). However, the direct interference of glucocorticoids with NF-
B DNA binding has only been demonstrated in transient cotransfection experiments (8). Whether this mechanism occurs in primary
cells, such as PBMC, remains to be determined. This mechanism was not examined in our studies and therefore cannot be ruled out as a mode of
interaction of MIF with hydrocortisone.
Glucocorticoid-induced increases in I
B
synthesis are believed to
be a direct influence of the glucocorticoid receptor-hormone complex on
the transcription rate of I
B
(13). It is possible that MIF may bind hydrocortisone (similar to the plasma glucocorticoid binding proteins), thereby preventing it from crossing either the
cellular or the nuclear membrane and associating with the intracellular
glucocorticoid receptor and activating I
B
transcription. However,
we could not demonstrate that MIF either bound hydrocortisone or
prevented it from associating with mononuclear cells. Alternatively, MIF may activate another cellular factor or pathway and thus indirectly interfere with the action of hydrocortisone on I
B
synthesis. This
indirect effect would suggest that MIF binds to a membrane receptor,
inducing secondary factors. However, receptors for MIF have not been
discovered to date. Therefore, the cellular pathway through which MIF
inhibits hydrocortisone induction of I
B
remains an open question.
Perspectives
In the present study, hydrocortisone in concentrations ranging from 50 to 200 ng/ml inhibited the LPS-stimulated decrease in cytosolic I
B
, thereby preventing NF-
B activation in human mononuclear
cells. The average morning circulating plasma concentration of
hydrocortisone is 130 ng/ml but can range from 50 to 250 ng/ml (10). Pharmacological doses of dexamethasone
(10
7 M, equivalent in biological potency to ~1,200
ng/ml of hydrocortisone) have previously been reported to prevent
NF-
B activation through increased I
B
expression in
TNF-
-stimulated Hela cells (1, 13). Our data indicate
that physiological doses of hydrocortisone also inhibit NF-
B
activation in human PBMC. Thus circulating hydrocortisone exerts an
anti-inflammatory effect, which may act as a constitutive brake on the
immune response. However, the data from this study suggest that MIF may
function to antagonize the anti-inflammatory effects of hydrocortisone
at normal circulating levels and therefore preserve the ability to
initiate an immune response. Therefore, MIF may play an important
immunomodulatory role within the relationship between the
hypothalamic-pituitary axis and mononuclear cells.
| |
ACKNOWLEDGEMENTS |
|---|
This study was supported by an National Institutes of Health (NIH) predoctoral training fellowship (GM-08619), NIH Grant AI-33414, and Pennsylvania State University General Clinical Research Center Grant RR-10732.
| |
FOOTNOTES |
|---|
Address for reprint requests and other correspondence: J. G. Cannon, 103 Noll Laboratory, Pennsylvania State Univ., Univ. Park, PA 16802 (E-mail: jgc2{at}psu.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Received 6 March 2000; accepted in final form 28 April 2000.
| |
REFERENCES |
|---|
|
|
|---|
1.
Auphan, N,
DiDonato JA,
Rosette C,
Helmberg A,
and
Karin M.
Immunosuppression by glucocorticoids: inhibition of NF-
B activity through induction of I
B synthesis.
Science
270:
286-290,
1995
2.
Baeuerle, PA,
and
Baltimore D.
NF-
B: Ten years after.
Cell
87:
13-20,
1996[ISI][Medline].
3.
Baeuerle, PA,
and
Henkel T.
Function and activation of NF-
B in the immune system.
Ann Rev Immunol
12:
141-179,
1994[ISI][Medline].
4.
Bernhagen, J,
Calandra T,
Mitchell RA,
Martin SB,
Tracey KJ,
Voelter W,
Manogue KR,
Cerami A,
and
Bucala R.
MIF is a pituitary-derived cytokine that potentiates lethal endotoxemia.
Nature
365:
756-759,
1993[Medline].
5.
Bozza, M,
Satoskar AR,
Lin G,
Lu B,
Humbles AA,
Gerard C,
and
David JR.
Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis.
J Exp Med
189:
341-346,
1999
6.
Calandra, T,
Bernhagen J,
Metz CN,
Spiege ILA,
Bacher M,
Donnelly T,
Cerami A,
and
Bucala R.
MIF as a glucocorticoid-induced modulator of cytokine production.
Nature
377:
68-71,
1995[Medline].
7.
David, JR.
Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction.
Proc Natl Acad Sci USA
56:
72-77,
1966
8.
De Bosscher, K,
Schimtx ML,
Vander Berghe W,
Plaisance PS,
and
Haegeman G.
Glucocorticoid-mediated repression of nuclear factor-kappaB-dependent transcription involves direct interference with transactivation.
Proc Natl Acad Sci USA
9:
13504-13509,
1997.
9.
Dignam, JD,
Lebovitz RM,
and
Roeder RG.
Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei.
Nucleic Acids Res
11:
1475-1488,
1983
10.
Genuth, SM.
The adrenal glands.
In: Physiology, edited by Berne R,
and Levy MN.. St. Louis, MO: Mosby Year Book, 1993, p. 949-979.
11.
Imamura, K,
Nishihira J,
Suzuki M,
Yasada K,
Sasaki S,
Kusunoki Y,
Tochimaru H,
and
Takekoshi Y.
Identification and immunohistochemical localization of macrophage migration inhibitory factor in human kidney.
Biochem Mol Biol Int
40:
1233-1242,
1996[ISI][Medline].
12.
Mikulowska, A,
Metz C,
Bucala R,
and
Holmdahl R.
Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type II-induced arthritis in mice.
J Immunol
158:
5514-5517,
1997[Abstract].
13.
Scheinman, RI,
Cogswell PC,
Lofquist AK,
and
Baldwin AS.
Role of transcriptional activation of I
B
in mediation of immunosuppression by glucocorticoids.
Science
270:
283-286,
1995
14.
Scheinman, RI,
Gualberto A,
Jewell CM,
Cidlowski JA,
and
Baldwin AS.
Characterization of mechanisms involved in transrepression of NF-
B by activated glucocorticoid receptors.
Mol Cell Biol
15:
943-953,
1995[Abstract].
15.
Shimizu, T,
Abe R,
Ohkawara A,
Mizue Y,
and
Nishihira J.
Macrophage migration inhibitory factor is an essential immunoregulatory cytokine in atopic dermatitis.
Biochem Biophys Res Commun
240:
173-178,
1997[ISI][Medline].
16.
Verma, IM,
Stevenson JK,
Schwartz EM,
and
Van Antwerp D.
Rel/NF-
B/I
B family: intimate tales of association and dissociation.
Genes Dev
9:
2723-2735,
1995
17.
Wada, S,
Fujimoto S,
Mizue Y,
and
Nishihira J.
Macrophage migration inhibitory factor in the human ovaries: presence in the follicular fluids and production by granulosa cells.
Biochem Mol Biol Int
41:
805-814,
1997[ISI][Medline].
18.
Wistow, GJ,
Shaughnessy MP,
Lee DC,
Hodin J,
and
Zelenka PS.
A macrophage migration inhibitory factor is expressed in the differentiated cells of the eye lens.
Proc Natl Acad Sci USA
90:
1272-1275,
1993
19.
Xu, D,
McSorley SJ,
Tetley L,
Chatfield S,
Dougan G,
Chan WL,
David JR,
and
Liew FY.
Protective effect of Leishmania major infection of migration inhibitory factor, TNF-
, and IFN-
administration orally via attenuated Salmonella typhimurium.
J Immunol
160:
1285-1289,
1998
This article has been cited by other articles:
![]() |
M. A. Amin, C. S. Haas, K. Zhu, P. J. Mansfield, M. J. Kim, N. P. Lackowski, and A. E. Koch Migration inhibitory factor up-regulates vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 via Src, PI3 kinase, and NF{kappa}B Blood, March 15, 2006; 107(6): 2252 - 2261. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Tripathy, P. Mohanty, S. Dhindsa, T. Syed, H. Ghanim, A. Aljada, and P. Dandona Elevation of Free Fatty Acids Induces Inflammation and Impairs Vascular Reactivity in Healthy Subjects Diabetes, December 1, 2003; 52(12): 2882 - 2887. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. K. Leung, S. C. W. Tang, L. Y. Y. Chan, A. W. L. Tsang, H. Y. Lan, and K. N. Lai Polymeric IgA increases the synthesis of macrophage migration inhibitory factor by human mesangial cells in IgA nephropathy Nephrol. Dial. Transplant., January 1, 2003; 18(1): 36 - 45. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Fingerle-Rowson, P. Koch, R. Bikoff, X. Lin, C. N. Metz, F. S. Dhabhar, A. Meinhardt, and R. Bucala Regulation of Macrophage Migration Inhibitory Factor Expression by Glucocorticoids in Vivo Am. J. Pathol., January 1, 2003; 162(1): 47 - 56. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |